Skip to main content
logo
Enveric Biosciences, Inc. (ENVB)
NASDAQ: ENVB · Real-Time Price · USD
2.150
+0.040 (1.90%)
At close: Feb 10, 2026, 4:00 PM EST
2.140
-0.010 (-0.47%)
After-hours: Feb 10, 2026, 7:46 PM EST

Company Description

Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders.

The company offers product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health.

It also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer.

The company was founded in 2020 and is headquartered in Cambridge, Massachusetts.

Enveric Biosciences, Inc.
Enveric Biosciences logo
CountryUnited States
Founded1994
IndustryBiotechnology
SectorHealthcare
Employees6
CEOJoseph Tucker

Contact Details

Address:
245 First Street, Riverview II
Cambridge, Massachusetts 02142
United States
Websiteenveric.com

Stock Details

Ticker SymbolENVB
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code890821
CUSIP Number29405E505
ISIN NumberUS29405E5050
Employer ID95-4484725
SIC Code2834

Key Executives

NamePosition
Dr. Joseph Edward Tucker Ph.D.Chief Executive Officer and Director
Kevin M. Coveney CPAChief Financial Officer
Dr. Peter J. Facchini Ph.D.Chief Innovation Officer

Latest SEC Filings

DateTypeTitle
Feb 10, 2026S-1General form for registration of securities under the Securities Act of 1933
Feb 6, 20268-KCurrent Report
Feb 6, 2026424B5Filing
Feb 4, 2026SCHEDULE 13GFiling
Feb 2, 2026SCHEDULE 13GFiling
Jan 28, 20268-KCurrent Report
Jan 28, 2026424B5Filing
Jan 9, 20268-KCurrent Report
Jan 5, 2026SCHEDULE 13G/AFiling
Dec 31, 2025424B3Prospectus
View All SEC Filings